Parathyroid Gland Carcinoma
Associated Genetic Biomarkers
NCI Definition: A malignant tumor arising from the parenchymal cells of the parathyroid gland. It is associated with the symptoms of primary hyperparathyroidism, resulting from the excessive production of parathyroid hormone. Morphologically, the differential diagnosis from parathyroid gland adenoma may be difficult. A definitive diagnosis of carcinoma is made only in the presence of capsular invasion, vascular invasion, and/or perineural invasion. 
There are 2 clinical trials for parathyroid gland carcinoma, of which 2 are open and 0 are completed or closed. Of the trials that contain parathyroid gland carcinoma as an inclusion criterion, 2 are phase 2 (2 open).
Ipilimumab, lutetium lu 177 dotatate, and nivolumab are the most common interventions in parathyroid gland carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.